| Detailed information |
|---|
| CancerLivER ID | 2560 |
| Biomarker | IL1A,IL1B,IL2,IL12A,IL12B,IL15,IFNG,TNF,IL4,IL5,IL8,IL10,CSF1,ANXA1,HLA-DRA,HLA-DPA1,PRG1 |
| Biomarker Name/Symbol (given in Publication) | IL1A,IL1B,IL2,IL12A,IL12B,IL15,IFNG,TNF,IL4,IL5,IL8,IL10,CSF1,ANXA1,HLA-DRA,HLA-DPA1,PRG1 |
| Biomolecule | RNAs |
| Subject | Human |
| Degree of Validity | Prognostic marker for prediction of HCC venous metastases and validated on independent dataset |
| Experimental Condition | Recurrence v/s non-recurrence |
| Cancer type | Hepatocellular carcinoma |
| Regulation | Diffrentially expressed between MIM (metastasis-inclined microenvironment) v/s MAM (metastasis-averse microenvironment ) |
| Level of significance | p < 0.05 |
| Source | Tissue |
| PMID | 16904609 |
| Type of Biomarker | Prognostic |
| Pathway | p53-mediated tumor suppres- sive pathway |
| Cohort | 115 Asian HCC patients: 52 MIM (primary HCC with venous metastases (major branch of the portal vein or inferior vena cava) or confirmed extrahepatic metastases by follow-up, which we termed a metastasis-inclined microenvironment or MIM) and 63 MAM (HCC without detectable metastases, which we termed |
| Sensitivity | 79% |
| Specificity | 67% |
| Accuracy | NA |
| AUC | NA |
| Disease | Recurrence v/s non-recurrence |
| Year of Publication | 2006 |
| Clinical trial | NO |
| Clinical trial (NCT Number) | NA |